title: Reply to D. Adkins et al.
authors.affiliation: Thomas Jefferson University Hospital, Philadelphia, PA rita.axelrod@jefferson.edu.
authors.forename: Rita S
authors.initials: RS
authors.lastname: Axelrod
authors.affiliation: Memorial Sloan Kettering Cancer Center, New York, NY.
authors.forename: Eric
authors.initials: E
authors.lastname: Sherman
authors.affiliation: The University of Texas MD Anderson Cancer Center, Houston, TX.
authors.forename: Adam
authors.initials: A
authors.lastname: Garden
authors.affiliation: Centre Hospitalier de l'Universite de Montreal, Montreal, Quebec, Canada.
authors.forename: Phuc Felix
authors.initials: PF
authors.lastname: Nguyen-Tan
authors.affiliation: H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL.
authors.forename: Andy
authors.initials: A
authors.lastname: Trotti
authors.affiliation: University of California, San Francisco, San Francisco, CA.
authors.forename: Sue S
authors.initials: SS
authors.lastname: Yom
authors.affiliation: Radiation Therapy Oncology Group Statistical Center, Philadelphia, PA.
authors.forename: Qiang
authors.initials: Q
authors.lastname: Zhang
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002294:Carcinoma, Squamous Cell / Q000628:therapy*; D059248:Chemoradiotherapy; D005260:Female; D006258:Head and Neck Neoplasms / Q000628:therapy*; D006801:Humans; D008297:Male